Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease-Reference-Cited by-同舟云学术

Characterization of Enhanced Behavioral Responses tol-DOPA Following Repeated Administration in the 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease

Published:1998-06 Issue:2 Volume:151 Page:334-342
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Henry Brian,Crossman Alan R.,Brotchie Jonathan M.

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference40 articles.

1. Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect;Ahlskog;Clin. Neuropharmacol.,1996

2. The clinical physiology of side effects in long-term L-dopa therapy;Barbeau;Adv. Neurol.,1974

3. Chronic treatment withl3;Bedard;Brain Res.,1986

4. Levodopa-induced dyskinesia: Facts and fancy. What dose the MPTP monkey model tell us;Bedard;Can. J. Neurol. Sci.,1992

5. Repeated apomorphine treatment causes behavioural supersensitivity and dopamine D2 receptor hyposensitivity;Bevan;Neurosci. Lett.,1983

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Construct, Face, and Predictive Validity of Parkinson’s Disease Rodent Models;International Journal of Molecular Sciences;2024-08-17

2. Therapeutic Viewpoint on Rat Models of Locomotion Abnormalities and Neurobiological Indicators in Parkinson's Disease;CNS & Neurological Disorders - Drug Targets;2024-04

3. Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson’s disease;Frontiers in Bioengineering and Biotechnology;2024-01-24

4. Altered amantadine effects after repetitive treatment for l-dopa-induced involuntary movements in a rat model of Parkinson’s disease;Neuroscience Letters;2023-05

5. Behavioral and neurochemical interactions of the tricyclic antidepressant drug desipramine with L-DOPA in 6-OHDA-lesioned rats. Implications for motor and psychiatric functions in Parkinson’s disease;Psychopharmacology;2022-09-30